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Since  the  discovery  of  cortisone  in the  1940s  and  its  early  success  in treatment  of rheumatoid  arthri-
tis, glucocorticoids  have  remained  the  mainstay  of  anti-inﬂammatory  therapies.  However,  cortisone
itself is  intrinsically  inert.  To  be effective,  it  requires  conversion  to  cortisol,  the  active  glucocorticoid,
by  the  enzyme  11-hydroxysteroid  dehydrogenase  type  1  (11-HSD1).  Despite  the  identiﬁcation  of
11-HSD  in  liver  in 1953  (which  we  now  know  to  be  11-HSD1),  its physiological  role  has  been  little
explored  until  recently.  Over  the  past  decade,  however,  it has  become  apparent  that  11-HSD1  playsineralocorticoid
1-Hydroxysteroid dehydrogenase
acrophage
nﬂammation
rthritis
an  important  role  in  shaping  endogenous  glucocorticoid  action.  Acute  inﬂammation  is  more  severe
with  11-HSD1-deﬁciency  or inhibition,  yet  in  some  inﬂammatory  settings  such  as  obesity  or  diabetes,
11-HSD1-deﬁciency/inhibition  is  beneﬁcial,  reducing  inﬂammation.  Current  evidence  suggests  both
beneﬁcial  and  detrimental  effects  may  result  from  11-HSD1  inhibition  in  chronic  inﬂammatory  disease.
Here we  review  recent  evidence  pertaining  to  the  role  of  11-HSD1  in  inﬂammation.
This  article  is  part  of  a  Special  Issue  entitled  ‘CSR  2013’.
© 2013 Elsevier Ltd. 
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. Introduction
The discovery of the anti-inﬂammatory effects of cortisone, a
lucocorticoid hormone, by Hench and colleagues in the 1940s,
pened the door to the longest and most successful drug devel-
pment programme in history. Glucocorticoids remain the most
idely prescribed treatment for inﬂammatory disease. They
otently affect both immune and non-immune cells, shaping their
esponses. Glucocorticoid actions are highly dependent on context
nd can be very different during acute and chronic inﬂamma-
ion. In the short term at least, many of their effects promote the
esolution of inﬂammation. Several years ago, we hypothesised
hat the glucocorticoid metabolising enzyme, 11-hydroxysteroid
ehydrogenase type 1 (11-HSD1), is induced early during an
nﬂammatory response and shapes its subsequent trajectory [1].
ow well has that hypothesis stood the test of time? Reasonably
ell as it turns out, but not in quite the way we had envisaged.
.1. Glucocorticoids and inﬂammation
Synthetic glucocorticoids exert potent anti-inﬂammatory and
mmunosuppressive effects and are widely prescribed to treat both
cute and chronic inﬂammation. Yet the well known side effects
f glucocorticoid excess include type 2 diabetes, visceral obesity,
ypertension and atherosclerosis which are themselves, somewhat
aradoxically, inﬂammatory conditions. Quite how glucocorticoids
rovoke inﬂammatory metabolic diseases at the same time as
uppressing chronic inﬂammatory conditions such as rheuma-
oid arthritis or inﬂammatory bowel disease remains unclear. It
s likely to involve more complex mechanisms than the commonly
eld view that the “adverse” metabolic effects involve gene acti-
ation by glucocorticoid receptor (GR), whereas the “beneﬁcial”
nti-inﬂammatory effects rely on gene repression. Fully under-
tanding how glucocorticoids cause “metabolic inﬂammation” will
e crucial for the development and optimal exploitation of future
nti-inﬂammatory therapies, which could manipulate glucocorti-
oid action in a more sophisticated manner than current therapies.
Understanding the role of endogenous glucocorticoids during
nﬂammation is key to achieving this aim. Endogenous glucocorti-
oids are vital to survive trauma or certain bacterial infections; they
uppress pro-inﬂammatory cytokine production, binding to GR in
mmune cells to prevent potentially lethal overshoot of immune
esponses [2,3]. Acutely, circulating pro-inﬂammatory cytokines
re a potent stimulus to the hypothalamic–pituitary–adrenal
HPA) axis to increase endogenous glucocorticoid production [4,5].
owever, this normal response is lost or attenuated in chronic
nﬂammation [6]. In this respect, the treatment of chronic inﬂam-
atory disease with exogenous glucocorticoids can be regarded as
eplacement therapy for an inadequate endogenous glucocorticoid
esponse [7].
Acute inﬂammation is an immediate response of the body to
njury or infection that serves to remove the injurious stimu-
us, then restore homeostasis by removal of dead and damaged
ells/tissues and engagement of repair processes. It is initiated
t the site of injury by the release of proinﬂammatory mediators
uch as bioactive amines, lipids and cytokines: typically tumour
ecrosis factor (TNF)- and interleukin (IL)-1. These cause vasodila-
ion, increase vascular permeability allowing exudation of plasma,
nd elicit leucocyte recruitment, activation and emigration from
he microcirculation to the damaged tissue. The initial response
s typically predominated by neutrophils, which are replaced by
onocytes/macrophages during the resolution and repair stages.
esolution of acute inﬂammation requires the engagement of
echanisms early in the inﬂammatory response that shape the
ubsequent resolution (reviewed in Refs. [8–10]). Chronic inﬂam-
ation results from persistence of the initiating stimulus withtry & Molecular Biology 137 (2013) 82– 92 83
associated lymphocyte and macrophage activation. Excessive tis-
sue damage contributes to continuing inﬂammation, failure of
resolution and dysregulated repair processes such as angiogene-
sis and ﬁbrosis and can thus form a “vicious” cycle. Whilst acute
inﬂammation frequently occurs and is contained entirely at the
local level, chronic inﬂammation invariably involves a systemic
response.
Glucocorticoids limit acute inﬂammation. They repress a large
number of proinﬂammatory genes, including pro-inﬂammatory
cytokines and chemokines, cell adhesion molecules and enzymes
involved in the initiation and/or maintenance of inﬂammation,
many of which are over-expressed in chronic non-resolving
inﬂammation. Conversely, they activate a number of genes encod-
ing anti-inﬂammatory mediators, such as IL-10 and annexin I
(reviewed in Refs. [11–13]). Thus, acutely, glucocorticoids inhibit
the initial vasodilation and increased vascular permeability dur-
ing inﬂammation. They also alter the balance between survival
and apoptosis of leukocytes as well as their distribution between
the circulation and immune tissues and they decrease leucocyte
emigration into sites of injury [13–18]. Importantly, glucocor-
ticoids potently inﬂuence the differentiation and phenotype of
immune cells, especially monocytes/macrophages and T lympho-
cytes, thereby polarising, or shaping, immune responses [19].
Glucocorticoid treatment of human monocytes promotes an
anti-inﬂammatory, pro-resolution phenotype, characterised by
high migratory and phagocytic capacity, expression of CD163
(haemoglobin scavenger receptor) and high production of IL-10
[20–23]. Similarly, in mice, pro-resolving macrophage functions
are enhanced by glucocorticoid treatment [24,25], thus shaping the
trajectory of an inﬂammatory response and its outcome. Because
glucocorticoids inhibit production of “Th1” cytokines, which pro-
mote a cell-mediated immune response (activation of phagocytes,
antigen-speciﬁc T lymphocytes) whilst preserving or promoting
“Th2” cytokine production (aiding antibody production), they also
shape the adaptive immune response.
Most research on the anti-inﬂammatory actions of glucocorti-
coids has utilised dexamethasone, a potent synthetic glucocorticoid
with powerful immunosuppressive properties. However, the
endogenous glucocorticoids, cortisol (the main glucocorticoid in
humans) and corticosterone (in rats and mice), are immunomodu-
latory rather than immunosuppressive [14,26], particularly when
administered at physiologically relevant concentrations. Indeed,
low doses of corticosterone stimulate whereas higher doses sup-
press macrophage activity [27]. This could, in part, reﬂect the higher
afﬁnity binding of endogenous glucocorticoids to the mineralo-
corticoid receptor (MR) (dexamethasone poorly activates MR  [28])
than to GR as both are expressed in macrophages [27,29,30]. How-
ever, whereas knock-down or antagonism of GR  in macrophages
abrogates responses to both high and low doses of corticosterone,
knock-down or antagonism of MR has little effect [27], suggest-
ing GR-mediated effects, at least in the rat macrophages tested.
The interplay between GR and MR  in macrophage function and
polarisation is likely to be complex (see below).
1.2. 11ˇ-Hydroxysteroid dehydrogenases modulate
glucocorticoid action
Endogenous glucocorticoids differ from dexamethasone in
another important respect; dexamethasone is not inactivated by
11-HSD activity [31] whereas endogenous glucocorticoids are
substrates for the 11-HSDs, which are important modulators
of physiological glucocorticoid action [32]. The 11-HSD “shut-
tle” interconverts active glucocorticoids (cortisol, corticosterone)
with their 11-keto forms (cortisone, 11-dehydrocorticosterone),
which bind poorly to receptors and are therefore intrinsically
inert. In intact cells, 11-HSD1 exhibits oxo-reductase activity,
84 K.E. Chapman et al. / Journal of Steroid Biochemistry & Molecular Biology 137 (2013) 82– 92
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olarisation of macrophages to an M1  phenotype further induces 11-HSD1 where
onocytes into macrophages in the presence of IL-4 and/or IL-13 further induces 1
onverting cortisone and 11-dehydrocorticosterone into active
ortisol and corticosterone respectively, increasing intracellular
lucocorticoid levels. In contrast, 11-HSD2 is exclusively a dehy-
rogenase, inactivating cortisol and corticosterone. Expression of
1-HSD2 is largely restricted to mineralocorticoid-target tissues,
ost notably the distal nephron of the kidney where it protects
he non-selective MR  from activation by glucocorticoids, conferring
ldosterone-speciﬁcity upon MR,  which is otherwise a high afﬁnity
lucocorticoid receptor [33,34]. Of the synthetic glucocorticoids in
idespread use as anti-inﬂammatory drugs, it is worth noting that
ome, including prednisone/prednisolone, are excellent substrates
or the 11-HSDs.
11-HSD1 is widely expressed, including in immune cells,
here its activity is dynamically regulated depending on cell acti-
ation state (reviewed in Ref. [35]). 11-HSD1 is up-regulated upon
ctivation of monocytes/macrophages, neutrophils or lymphocytes
35,36] (and see Fig. 1). Circulating leukocytes in mice and healthy
umans do not express 11-HSD2 [1,37]. Both 11-HSD isozymes
re regulated by pro-inﬂammatory signalling in non-immune cells
see below for details).
.3. 11ˇ-HSD1 expression in monocytes/macrophages depends
n cell activation state
Monocytes and macrophages are essential during an inﬂam-
atory response. In response to diverse environmental signals,
resting” or naïve macrophages adopt distinct phenotypes. These
re broadly categorised based on in vitro experiments into two
tates, M1  (or classically activated) and M2  (or alternatively acti-
ated) (reviewed in Refs. [38,39]). M1  macrophages, induced
y interferon- and Toll-like receptor (TLR) activation (e.g. by
ipopolysaccharide, LPS), are vital for host defence, expressing pro-
nﬂammatory cytokines, inducible nitric oxide synthase (iNOS)
nd demonstrating strong microbicidal activity. M2  macrophages,
olarised with IL-4 and/or IL-13, restore homeostasis in the repair
hase of inﬂammation. They are also vital for parasite elimina-
ion. Other stimuli induce M2-like anti-inﬂammatory phenotypes,
istinct from IL-4/IL-13 polarised macrophages. Macrophage phe-
otype in vivo may  be more complex and heterogeneous [40],
specially macrophages with M2-like characteristics, reﬂectingnegligible in human monocytes, but is induced on differentiation into macrophages.
risation to an M2 phenotype has no further effect on expression. Differentiation of
D1 (see text for details).
the diversity of signalling and context in vivo. Glucocorticoids
restrain M1  macrophages, dampening pro-inﬂammatory cytokine
expression, and in naïve monocytes/macrophages, induce a highly
phagocytic, highly motile, M2-like phenotype [21,24,41]. Condi-
tional deletion of GR in macrophages increases pro-inﬂammatory
cytokine production and mortality following LPS administration
[3,42]. Conversely, conditional deletion of MR  in macrophages pro-
motes polarisation to an alternatively activated (M2) phenotype
[43], suggesting a possible reciprocal relationship between GR and
MR activation in macrophages. There is therefore considerable
potential for 11-HSD1 (which can potentially supply ligand to
either receptor) to modulate monocyte/macrophage phenotype by
increasing intracellular glucocorticoid levels, even in the absence
of elevated circulating glucocorticoid levels.
Expression of 11-HSD1 is low in circulating mouse leukocytes
but is higher in macrophages [44]. Though negligible in non-
stimulated human monocytes, 11-HSD1 expression is induced
upon differentiation into resting or naïve (i.e. unstimulated)
macrophages [37]. M1  polarisation of naive macrophages with LPS
further induces 11-HSD1 (Figure 1). In contrast, polarisation to
an M2  phenotype with IL-4 has little effect on 11-HSD1 expres-
sion [45,46]. However, in human monocytes differentiated into
macrophages in the presence of IL-4 (which may induce a distinct
anti-inﬂammatory macrophage phenotype from M2  polarisation
of resting macrophages), 11-HSD1 activity is as high or higher
than in M1,  and is further increased by peroxisome proliferator-
activated receptor (PPAR)- activation [47]. In contrast, in mouse
bone marrow-derived macrophages (resting macrophages) PPAR
agonists down-regulate 11-HSD1 expression [47]; whether
this reﬂects a mouse/human species difference or the differ-
ent macrophage phenotypes (resting mouse macrophages versus
human macrophages differentiated in the presence of IL-4) is cur-
rently unclear. Nevertheless these studies illustrate a complex
dependence of 11-HSD1 expression upon macrophage activation
state. The signiﬁcance is currently unknown but might reﬂect (or
inﬂuence) differences in energy metabolism between glycolytic M1
and oxidative M2  macrophages [48,49]. Recent evidence suggests
manipulation of glucose metabolism in macrophages directly alters
polarisation [49]. Whether alterations in 11-HSD1 expression
inﬂuence macrophage glucose metabolism, for example through
K.E. Chapman et al. / Journal of Steroid Biochemistry & Molecular Biology 137 (2013) 82– 92 85
Fig. 2. Macrophage polarisation is associated with a switch in energy metabolism. M1 macrophages show a predominantly glycolytic metabolism. High levels of glucose-6-
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whosphate (G6P) may  ensure a ready supply of NADPH cofactor to 11-HSD1, drivin
ith  lower levels of glycolysis and lower levels of 11-HSD1 converting E to F. Wh
s  currently unknown (see text for details).
he coupling of 11-HSD1 oxo-reductase activity to hexose 6-
hosphate activity in the endoplasmic reticulum (see below) is an
mportant question to address as it may  directly affect polarisation
r the extent of activation of macrophages. Dynamic regulation of
1-HSD1 in macrophages could therefore be crucial to the ability
o shape an ongoing inﬂammatory response, either through intra-
ellular regeneration of glucocorticoids or indirectly by diversion
f glucose-6-phosphate (Fig. 2). Evidence for dynamic regulation
f 11-HSD1 during an inﬂammatory response in vivo comes from
he rapid induction of 11-HSD1 activity in neutrophils and mono-
ytes/macrophages during sterile peritonitis in mice; 11-HSD1
ctivity decreases as the inﬂammation resolves [1,36]. The lat-
er is possibly an active process; 11-HSD1 activity is rapidly
own-regulated in macrophages that have phagocytosed apoptotic
eutrophils [35], a highly pro-resolution process [50]. This reason-
ng led to the hypothesis that the early induction of 11-HSD1
n macrophages increases glucocorticoid action within these cells,
romoting an anti-inﬂammatory phenotype and leading to more
apid resolution of inﬂammation [1,51].
.4. 11ˇ-HSD1 in acute inﬂammation – regulation
In most animal models of acute inﬂammation 11-HSD1 activ-
ty is up-regulated in the inﬂamed tissue, whereas 11-HSD2 (if
xpressed at all) is down-regulated. This is true of the inﬂamed
olon and the arthritic joint [52–54], but not the vasculature
55]. This switch in the balance of 11-HSD1 and 2 activi-
ies is predicted to increase paracrine/autocrine glucocorticoid
ction, though this has not been directly tested. Induction of
1-HSD1 (and repression of 11-HSD2) at inﬂamed sites is prob-
bly due to local release of the pro-inﬂammatory cytokines IL-1
nd TNF which stimulate transcription of the 11-HSD1 gene
romoter through increased binding of the transcriptional regula-
ors CCAAT/enhancer binding protein (C/EBP)- and nuclear factor
appa-light-chain-enhancer of activated B cells (NF-B) [56–58]
nd repress the 11-HSD2 gene promoter through an early growth
esponse (EGR)-1 and NF-B-dependent mechanism [59]. Nor-
ally glucocorticoids antagonise TNF- or IL-1 action, but theyct together with the pro-inﬂammatory cytokines to synergis-
ically increase 11-HSD1 expression in a variety of cell types
60–63]. This is predicted to amplify the effect of glucocorticoid
ithin a given cell or tissue, more rapidly promoting the repair and conversion of cortisone (E) to cortisol (F). M2  polarised macrophages are oxidative,
hanges in energy metabolism drive changes in macrophage 11-HSD1 expression
resolution phase. Whether 11-HSD1 expression in inﬂammatory
cells is regulated by similar mechanisms is an interesting question.
Neither TNF- nor IL-1 affect 11-HSD1 activity in monocytes
[37] and the signalling pathways that regulate macrophage 11-
HSD1 expression have not been characterised. C/EBP, a key
regulator of 11-HSD1 transcription in a variety of cell types
[56,57,64–68], mediates M2  polarisation and arginase expression
[69] yet also plays a role in pro-inﬂammatory cytokine expres-
sion in M1  macrophages [70]. However, genetic deletion of C/EBP
abolishes both the liver-enriched inhibitor protein (LIP) and liver-
enriched activator protein (LAP) C/EBP  isoforms, the balance of
which potently inﬂuences 11-HSD1 mRNA levels in vivo [71]
and also regulates osteoclast differentiation [72], a process akin
to macrophage differentiation. The C/EBP-LIP:LAP ratio is regu-
lated by mTOR [73], an integrator of cellular nutrient and energy
metabolism, that is downstream of phosphatidylinositol 3-kinase
(PI3K) and Akt, both capable of polarising macrophages [74,75].
Plausibly, the C/EBP-LIP:LAP ratio differs according to the acti-
vating stimulus and may  govern the expression level of 11-HSD1
in polarised macrophages. The coupling within the endoplasmic
reticulum of 11-HSD1 activity to the supply of NADP(H) cofactor
generated by hexose-6-phosphate dehydrogenase (H6PD) [76–78]
is particularly intriguing in this respect, as it raises the possibility
that cellular glucose availability and ﬂux through the endoplasmic
reticulum pentose phosphate pathway (the ﬁrst 2 steps of which
are catalysed by H6PD) controls 11-HSD1 activity [79] which may
therefore differ irrespective of expression levels in M1  and M2
macrophages.
1.5. 11ˇ-HSD1 in acute inﬂammation – function
Based on the expression of 11-HSD1 in macrophages, its induc-
tion early during an inﬂammatory response and the well-known
anti-inﬂammatory effects of glucocorticoids, it was  anticipated
that 11-HSD1 deﬁciency or inhibition would attenuate local
glucocorticoid production and thus worsen acute inﬂammation.
This is indeed what is seen in 11-HSD1-deﬁcient (Hsd11b1−/−)
mice, with more severe LPS-induced endotoxaemia (classically
repressed by glucocorticoids [3,80]), an earlier onset of inﬂam-
mation in the K/BxN serum transfer model of inﬂammatory
arthritis and more inﬂammatory cells (both neutrophils and mono-
cytes/macrophages) recruited in sterile peritonitis or pleuritis and
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n the injured myocardium following myocardial infarction [81–83]
and see Fig. 3). This increase in inﬂammation could reﬂect greater
ecruitment and/or delayed clearance/apoptosis of neutrophils
1,84]. In support of the latter, Hsd11b1−/− mice show delayed
acrophage acquisition of phagocytic capacity for apoptotic neu-
rophils as well as an increase in the number of free apoptotic
eutrophils during sterile peritonitis, although surprisingly the
eritonitis resolves at the same time as in wild-type mice [1].
lso surprising was the ﬁnding that despite the increased inﬂam-
ation early following myocardial infarction or possibly because
f it, heart function post-infarction is much better preserved in
sd11b1−/− mice than in controls. Underlying the improved recov-
ry from myocardial infarction is an increased angiogenic response
o injury [85], probably as a consequence of an earlier accumu-
ation of reparative M2  (Ym1+) macrophages and higher levels
f the pro-angiogenic cytokine IL-8 in the hearts of Hsd11b1−/−
ice [82]. It will be important to determine how generally this
ccelerated switch in macrophage phenotype from M1  to M2
pplies to inﬂammation in Hsd11b1−/− mice; so far it has only
een reported in myocardial infarction and M2-like polarisation
s not a general feature of 11-HSD1-deﬁcient macrophages, at
east in vitro [1,81] or in vivo, in adipose tissue of high fat fed
bese mice [86]. Despite the lack of detectable difference in
dipose tissue macrophage phenotype, an increased angiogenic
esponse to tissue ischaemia is also seen in adipose tissue of obese
sd11b1−/− mice and underlies their resistance to some of the
dverse metabolic consequences of obesity [87], suggesting the
ro-angiogenic phenotype may  be at least partly independent of
acrophages.
How is the improved recovery of Hsd11b1−/− mice from
nﬂammation following myocardial infarction reconciled with our
riginal hypothesis? As predicted by the hypothesis, deﬁciency in
1-HSD1 causes greater release of pro-inﬂammatory cytokines
rom LPS-treated macrophages [1,81], suggesting an exaggerated
1 macrophage phenotype. However, the earlier switch to an M2
henotype was unexpected. Whether this reﬂects a switch to M2
henotype in situ or recruitment of a distinct subset of monocytes
s currently unknown. It is possible that this is a consequence of
rolonged activation of the HPA axis in Hsd11b1−/− mice. However,
hese mice show little perturbation of plasma corticosterone lev-
ls, even following stress, on this genetic background [88], so the
arlier switch is unlikely to be mediated by plasma glucocorticoids.
oreover, as discussed above, intracellular ampliﬁcation of gluco-
orticoid signalling by 11-HSD1 is predicted to accelerate repair
nd resolution processes, not attenuate them. Several key fac-
ors implicated in macrophage polarisation [89] are differentially
xpressed in Hsd11b1−/− mice. The Src homology 2-containing
nositol-5′-phosphatase (SHIP)-1 negatively regulates the PI3K
athway. It represses the generation of M2  macrophages [74] yet
estrains LPS-induced (M1) activation of bone marrow-derived
naïve) macrophages [90]. Moreover, elevated SHIP1 expression
nduces endotoxin tolerance [90] with reduced pro-inﬂammatory
ytokine production with subsequent endotoxin challenge [90].
he increased LPS-responsiveness of thioglycollate elicited perit-
neal (TEP) macrophages from Hsd11b1−/− mice was  attributed
o elevated SHIP1 levels as a consequence of higher levels of
GF [81] though SHIP1 levels appear to decrease more rapidly
ollowing LPS in Hsd11b1−/− macrophages than in wild-type. In
pleenic macrophages, basal SHIP1 levels are normal in Hsd11b1−/−
ice, but unlike wild-type spleenic macrophages, those from
sd11b1−/− mice fail to down-regulate SHIP1 following LPS [81].
hether this induces endotoxin tolerance [90] to a greater extent in
sd11b1−/− macrophages is something that requires testing. Thus,
HIP1 appears abnormally regulated in Hsd11b1−/− macrophages,
hough why is currently unclear. Nevertheless, these somewhat
onfusing data illustrate that M1/M2  macrophage polarisation intry & Molecular Biology 137 (2013) 82– 92
Hsd11b1−/− mice may  be highly dependent upon the macrophage
population and context.
Hypoxia-inducible factor (HIF1)-,  which promotes M1  polari-
sation, is decreased in adipose tissue of Hsd11b1−/− mice, whereas
levels of PPAR (which promotes the M2  phenotype) are increased
[87,91]. Whether these factors are differentially expressed in
macrophages of Hsd11b1−/− mice will be important to determine.
The outcome of acute inﬂammation is not invariably improved
in Hsd11b1−/− mice. At the stage when arthritis has largely
resolved in wild-type mice following K/BxN serum transfer,
joints of Hsd11b1−/− mice show greater periarticular ﬁbrosis,
more extensive exostoses and ganglion cyst formation. Following
carageenan-induced pleurisy, Hsd11b1−/− mice show persistence
of inﬂammation at a stage when it is resolving in wild-type con-
trols, as well as lymphoid aggregates within the lung and formation
of ﬁbrous adhesions between lung lobes, the latter not present in
control mice [83]. Whether these disadvantageous features result
from greater inﬂammation in Hsd11b1−/− mice, an earlier switch
to a pro-repair (pro-ﬁbrotic) M2  phenotype, a greater response of
the non-immune tissue or a combination of all of these will be an
interesting question for the future. Moreover, the consequences of
more extended inﬂammation will be interesting to determine. The
preliminary ﬁndings in arthritis and carageenan induced pleurisy
suggest that 11-HSD1-deﬁciency or inhibition may  aggravate dis-
eases associated with a dysregulated angiogenic and pro-ﬁbrotic
phenotype, including rheumatoid arthritis.
1.6. Chronic inﬂammation
Chronic inﬂammation results from a failure to resolve acute
inﬂammation. Atherosclerosis, diabetes, metabolic syndrome and
Alzheimer’s disease are all now recognised as chronic inﬂamma-
tory diseases. Even simple obesity is frequently associated with
low level chronic inﬂammation within the adipose tissue. The
elevation in systemic pro-inﬂammatory cytokines during chronic
inﬂammation might be expected to activate the HPA axis. How-
ever, plasma cortisol is normal in both the “classic” inﬂammatory
diseases (rheumatoid arthritis, inﬂammatory bowel disease, etc.)
and in the “metabolic” inﬂammatory diseases (atherosclerosis,
metabolic syndrome, diabetes), at least until these become compli-
cated by additional pathologies. HPA axis activity may be elevated
in metabolic inﬂammation, with increased clearance of glucocorti-
coids maintaining normal plasma cortisol levels [92] but possibly
increasing plasma cortisone levels (and thus 11-HSD1 substrate),
though this has only been indirectly measured. In rheumatoid
arthritis and other inﬂammatory diseases however, the HPA axis
appears relatively suppressed, especially given the level of sys-
temic inﬂammation expected to activate the axis [4,93]. Edwards
has recently hypothesised that this apparent deﬁciency in HPA
axis activation is a result of the systemic increase in TNF- in
chronic inﬂammation inducing a widespread increase in 11-HSD1
expression, including in the hypothalamus, thus amplifying neg-
ative feedback by glucocorticoids on the HPA axis [93]. Whether
this is indeed the case requires experimental testing, but consistent
with this hypothesis, whole body conversion of cortisone to corti-
sol (relative to cortisol to cortisone) is increased in patients with
inﬂammatory disease [94] suggesting altered balance of 11-HSD
activities in favour of 11-reductase (11-HSD1).
1.7. Metabolic syndrome, type 2 diabetes and atherosclerosis11-HSD1 deﬁciency or inhibition is metabolically beneﬁcial
in rodent models of diet-induced obesity or diabetes. It improves
hepatic and adipose insulin sensitivity, attenuates hepatic glu-
coneogenesis, skews to a “cardioprotective” plasma lipid proﬁle,
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Fig. 3. Effects of 11-HSD1 deﬁciency/inhibition on acute and chronic inﬂammation. Deﬁciency or inhibition of 11-HSD1 worsens or exaccerbates acute inﬂammation, but
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nﬂammatory cell recruitment to sites of inﬂammation and promoting insulin se
ro-ﬁbrotic phenotype of 11-HSD1 deﬁciency/inhibition may  worsen tissue dama
hifts hepatic lipid metabolism from lipogenesis to fatty acid oxi-
ation and causes a preferential gain of peripheral adipose tissue at
he expense of visceral [86,91,95–101] (and see Fig. 3). Similarly, in
atients with type 2 diabetes, 11-HSD1 inhibition lowers plasma
lucose and lipids, consistent with rodent studies. It also modestly
educes blood pressure in human hypertension [102–104]. Intrigu-
ngly, an 11-HSD1 inhibitor more effectively improved glucose
omeostasis in obese mice when administered close to the time
f the diurnal peak of plasma glucocorticoid levels [105]. Given
hat 11-HSD1 mRNA probably does not vary with the circadian
hythm [105,106] (though one study suggests it may  in rats [107]),
his is much more likely to reﬂect high 11-HSD1 substrate levels
t peak HPA axis activity [108]. Indeed, 11-HSD1 may  contribute
o normal circadian control of the HPA axis, at least in some genetic
ackgrounds [88,108]. 11-HSD1 is expressed in the paraventric-
lar nucleus of the human hypothalamus, suggesting a conserved
ole in HPA axis regulation [109].
Recent data suggest that the liver is not the sole or even
redominant target of the metabolically beneﬁcial effects of 11-
SD1-deﬁciency or inhibition; conditional deletion of 11-HSD1 in
epatocytes of mice produces only minimal improvements in glu-
ose homeostasis in diet-induced obesity [110]. Instead, increased
lucocorticoid activity in adipose tissue is implicated. In obese
umans, numerous studies have reported elevated 11-HSD1
xpression in subcutaneous adipose tissue (reviewed in Ref. [92])
nd in human omental fat, 11-HSD1 expression correlates with
dipocyte hypertrophy [111,112], itself associated with a more
ro-inﬂammatory state [113,114]. In mice, a two  to three-fold ele-
ation of 11-HSD1 selectively in adipose tissue phenocopies the
etabolic syndrome, with central obesity, insulin resistance, dys-
ipidaemia and hypertension [115,116] whereas similar transgenic
xpression of 11-HSD2 in adipocytes (it is not normally expressed
n adipocytes), presumably lowering intra-adipose glucocorticoid
ction, causes insulin sensitisation in high fat fed mice [117].
11-HSD1-deﬁciency protects against pro-inﬂammatory
hanges in adipose tissue in obesity. Inﬂammatory cell
macrophages, lymphocytes) inﬁltration of mesenteric adi-
ose tissue is lower in high fat-fed 11-HSD1-deﬁcient mice
han in controls, probably due to reduced adipocyte secretion of
he pro-inﬂammatory chemokine, monocyte chemoattractant-1y, atherosclerosis, diabetes), 11-HSD1 deﬁciency/inhibition is beneﬁcial, reducing
ation. However, during chronic non-resolving inﬂammation, the pro-angiogenic,
e text for details).
(MCP-1) [86]. This is associated with higher levels of AMP-activated
protein kinase activation in this depot [86], likely to contribute to
the maintained lipid oxidation with obesity [118] in 11-HSD1-
deﬁciency. Whether these changes are a cause or a consequence of
the increase in angiogenesis and reduction in hypoxia and ﬁbrosis
recently described in the adipose tissue of these mice [87] is an
interesting question. Adipose tissue hypoxia is associated with a
local pro-inﬂammatory environment and leads to ﬁbrosis though
not necessarily angiogenesis [119–121], suggesting that it is the
greater angiogenic response in Hsd11b1−/− mice that is protective
against adipose tissue hypoxia and ﬁbrosis. PPAR mRNA levels
are higher and the pro-angiogenic response to PPAR activation is
much greater in Hsd11b1−/− adipocytes than in controls, placing
the adipocyte at the heart of the response. Whether there are
also beneﬁcial roles for macrophage and/or vascular 11-HSD1 is
important to determine.
As well as improving metabolic risk factors, deﬁciency in or
inhibition of 11-HSD1 also reduces atherosclerosis and systemic
inﬂammation and lowers macrophage and T cell inﬁltration of
atherosclerotic lesions in Apoe−/− mice [122–124]. This is the
converse of what happens with 11-HSD2-deﬁciency, which is pro-
inﬂammatory in the endothelium and accelerates atherosclerosis in
Apoe−/− mice, an effect at least partly mediated through activation
of the MR  as it is blocked by eplerenone, an MR  antagonist [125].
The atheroprotective effects of 11-HSD1-deﬁciency are likely to
be mediated through both systemic (reduced circulating mono-
cyte chemotactic protein (MCP)-1 and number of pro-inﬂammatory
Ly6Chi monocytes) and local (reduced aortic vascular cell adhesion
molecule (VCAM)-1 expression) mechanisms [124]. It is interest-
ing to speculate that reduced visceral adipose tissue inﬂammation
may  contribute to the reduction in systemic inﬂammation – as in
diet-induced obesity, mesenteric adipose tissue MCP-1 mRNA lev-
els are reduced in western diet-fed 11-HSD1-deﬁcient Apoe−/−
mice [124].
1.8. “Classic” inﬂammatory diseases – rheumatoid arthritisIf 11-HSD1-deﬁciency is beneﬁcial in chronic “cardiometabolic
inﬂammation”, what of the classical inﬂammatory diseases,
in which a glucocorticoid-insufﬁcient state is suggested and
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lucocorticoid therapy remains highly effective? Inevitably, stud-
es in animals are predominantly short term, modelling the disease,
hereas the disease in patients frequently reﬂects years of accu-
ulated damage and inﬂammation. These situations may  be quite
ifferent. Nevertheless, accumulating evidence in both patients and
nimal models is consistent with dysregulated 11-HSD1 in the
nﬂamed joint in rheumatoid arthritis as well as increased colonic
xpression of 11-HSD1 at sites of inﬂammation in inﬂammatory
owel disease (reviewed in Ref. [35]). So far, studies in inﬂamma-
ory bowel disease have gone little beyond observation, though
hey do suggest that at least some of the increase in 11-HSD1
xpression occurs in activated lymphocytes that migrate from the
nﬂamed colon to the draining lymph nodes [54]. Studies in human
atients with rheumatoid arthritis suggest differential regulation
f 11-HSDs in immune and mesenchymal cells. Comparison of
ortisone and cortisol levels in synovial ﬂuid and serum suggest
he balance favours intra-articular generation of cortisol in the
heumatic joint [126] although it seems that even so, the over-
ll capacity to convert cortisone to cortisol may  be reduced in the
nﬂamed arthritic synovium compared to non-inﬂamed. However,
ithin inﬂamed rheumatic joints, synovial inﬂammation still cor-
elates with conversion of cortisone to cortisol [127]. This complex
elationship probably reﬂects the balance between high expression
f 11-HSD1 in synovial ﬁbroblasts from arthritic patients (almost
ertainly as a result of the pro-inﬂammatory cytokine environ-
ent) and expression of 11-HSD2 in synovial macrophages from
atients with rheumatoid arthritis [126–128]. This latter ﬁnding
ccords with other studies identifying 11-HSD2 as a periph-
ral blood mononuclear cell marker of early rheumatoid arthritis
nd highly expressed in the arthritic joint [129,130]. 11-HSD2-
ositive macrophages have also been described in the lungs of
atients who died of acute respiratory distress syndrome [131].
imilar cells (macrophages, lymphocytes) from healthy humans
o not express 11-HSD2 [37,130], nor has 11-HSD2 been found
n mouse leukocytes [1]. 11-HSD2 expression in leukocytes may
eﬂect a species difference between mouse and human, or could,
n humans, reﬂect an adaptive response to chronic inﬂammation.
he biological reason for this apparently pro-inﬂammatory change
s unknown but it is likely to cause resistance to endogenous gluco-
orticoids, which might be overcome by pharmacological levels of
ynthetic glucocorticoids like prednisolone or bypassed with non-
etabolised synthetic glucocorticoids like dexamethasone.
What might 11-HSD1 inhibition do in chronic inﬂammatory
isease? If the Edwards hypothesis [93] is correct, then sys-
emic inhibition of 11-HSD1, particularly if administered during
he night (in humans), should correct the HPA axis abnormal-
ty and boost the plasma cortisol levels. This might be enough
o dampen down some of the inﬂammation, though 11-HSD1
nhibition would also deprive inﬂamed tissues of the 11-HSD1-
ediated increase in intracellular glucocorticoid levels. Moreover,
iven that cortisol also activates MR  (in the absence of 11-HSD2),
his could further exacerbate inﬂammation which could be par-
icularly damaging within the vasculature (see below). In chronic
nﬂammatory disease, continuing tissue injury is frequently asso-
iated with ﬁbrosis and angiogenesis. Both may  be exacerbated
y 11-HSD1 inhibition. As mentioned above, 11-HSD1-deﬁcient
ice show an increased angiogenic response to adipose tissue
ypoxia, to ischaemia following myocardial infarction, in wound
ealing and in sub-cutaneously implanted sponges [85,87]. They
lso show a pro-ﬁbrotic response to pleural inﬂammation and fol-
owing inﬂammatory arthritis [83]. Whilst it is currently unclear
hether the increased ﬁbrosis in 11-HSD1-deﬁcient mice willesolve completely during recovery from inﬂammation, it is likely
hat if the injurious stimulus persists, ﬁbrosis will be more severe
ith 11-HSD1-deﬁciency or inhibition. In continuing liver injury,
 population of macrophages with “M2”-like properties drives thetry & Molecular Biology 137 (2013) 82– 92
ﬁbrotic response, probably mediated at least in part through TGF1
[40]. Higher macrophage expression of TGF1 with 11-HSD1-
deﬁciency [81] may  be an important contributor to the pro-ﬁbrotic
phenotype of these mice.
1.9. Glucocorticoid receptor or mineralocorticoid receptor
activation?
Activation of MR,  most notably in the heart and vasculature, has
pro-inﬂammatory and pro-ﬁbrotic consequences [132,133]. Unlike
synthetic glucocorticoids, most of which show selectivity for GR
over MR,  endogenous glucocorticoids bind with higher afﬁnity to
MR than to GR. Thus, MR  is usually considered near saturated at
circulating glucocorticoid levels, even at the diurnal nadir [134].
Aldosterone activates MR  irrespective of which cells it is expressed
in, but cortisol activation of MR  is normally prevented if 11-HSD2
is co-expressed with MR.  However, under conditions of oxidative
stress, endogenous glucocorticoids can activate MR,  at least in the
cardiovascular system [135]. A crucial question therefore, central
to the function of 11-HSD1, is which receptor binds the ligand
it generates, GR or MR?  This may differ according to tissues. MR  is
absent from liver, so in this tissue, 11-HSD1 provides ligand to GR.
However, MR  is expressed in some classical glucocorticoid targets,
including adipocytes and macrophages, normally in the absence
of 11-HSD2, where it presumably functions as a glucocorticoid
receptor. A pro-inﬂammatory role for glucocorticoid-activated MR
is suggested; eplerenone treatment of ob/ob mice prevented the
obesity-associated increases in MCP-1, TNF- and other inﬂam-
matory markers in adipose tissue [136]. Whether the relevant
cell is the adipocyte, however, is unclear. Whereas MR activa-
tion (presumably by glucocorticoids) in macrophages appears
pro-inﬂammatory, macrophage-speciﬁc deletion of MR  appears
anti-inﬂammatory – it causes M2  polarisation of macrophages [43]
and reduces cerebral infarct area following ischaemia in mice,
concomitant with reduced expression of M1  macrophage mark-
ers (TNF-, IL-1, MCP-1, etc.) but maintained M2 markers (Ym1,
Arg1) [137]. Thus, the consequences of 11-HSD1-mediated glu-
cocorticoid generation could differ greatly, depending on cellular
oxidation/stress state and the relative levels of GR versus MR.
2. Summary and conclusions
Consistent with the adverse metabolic effects of glucocorticoid
excess, 11-HSD1 deﬁciency or inhibition is clearly beneﬁcial in
cardiometabolic disease. The extent to which this is dependent
on inhibition/deﬁciency within inﬂammatory cells will be inter-
esting to discover. Also, whether 11-HSD1 deﬁciency/inhibition
is beneﬁcial in other types of inﬂammation remains to be seen.
Current evidence suggests that the acute response to injury is
more severe. The subsequent recovery phase may  depend on
whether the injurious stimulus persists as in patients with rheuma-
toid arthritis (in which case 11-HSD1 deﬁciency/inhibition may
worsen the disease), or whether recovery and tissue remod-
elling occur, as for example follows myocardial infarction (when
11-HSD1 deﬁciency/inhibition may  aid recovery). The applica-
tion of Cre/Lox technology to generate tissue- and cell-speciﬁc
“knock-out” of 11-HSD1 will be invaluable in dissecting the
contributions of immune cells, particularly macrophages and neu-
trophils, to the pro-angiogenic and pro-ﬁbrotic phenotype. In the
future, such studies could lead to better targeting of glucocorti-host tissues at speciﬁc temporal stages of disease. As already sug-
gested [1], targeted delivery of inactive glucocorticoid precursors to
macrophages might provide an effective future therapy for chronic
inﬂammatory disease.
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